Scarica l'app Stockscreener
14.94
2.61%
-0.40
Dopo l'orario di chiusura:
15.06
0.12
+0.80%
Precedente Chiudi:
$15.34
Aprire:
$15.48
Volume 24 ore:
893.20K
Relative Volume:
1.11
Capitalizzazione di mercato:
$918.08M
Reddito:
-
Utile/perdita netta:
$-219.88M
Rapporto P/E:
-4.012
EPS:
-3.7238
Flusso di cassa netto:
$-175.76M
1 W Prestazione:
+16.63%
1M Prestazione:
+3.53%
6M Prestazione:
+104.38%
1 anno Prestazione:
+80.65%
Intervallo 1D:
$14.21
$15.75
Intervallo di 1 settimana:
$12.42
$15.90
Portata 52W:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
14.94 | 942.66M | 0 | -219.88M | -175.76M | -3.7238 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Iniziato | Citigroup | Buy |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-08-21 | Ripresa | H.C. Wainwright | Buy |
| 2025-06-11 | Ripresa | Stifel | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Insider sales at CGEM (NASDAQ: CGEM) include 8,000-share 10b5-1 trade - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6%Time to Sell? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CGEM Reiterates by BTIG -- Price Target Maintained at $38.00 - GuruFocus
Cullinan Therapeutics (NASDAQ:CGEM) Trading 8.5% HigherHere's Why - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives "Buy" Rating from BTIG Research - MarketBeat
Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Michaelson Jennifer - Moomoo
Cullinan wins FDA review for cancer therapy developed with Taiho - MSN
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst (NASDAQ:CGEM) - Seeking Alpha
H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Research Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat
Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $38 - Moomoo
Cullinan Therapeutics' (CGEM) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
CGEM Maintained by HC Wainwright & Co. -- Price Target Raised to $30 - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics Inc files for mixed shelf offering - marketscreener.com
Cullinan,Taiho win FDA review for cancer therapy (CGEM:NASDAQ) - Seeking Alpha
CGEM Secures FDA Acceptance for Zipalertinib NDA - GuruFocus
Cullinan Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers - Moomoo
Cullinan Therapeutics (NASDAQ: CGEM) launches $200M ATM with TD Cowen - Stock Titan
Cullinan Therapeutics NDA for zipalertinib in advanced NSCLC accepted by FDA - Traders Union
Cullinan Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Cullinan Therapeutics | DEF 14A: Definitive information statements - Moomoo
Cullinan Therapeutics | DEFA14A: Others - Moomoo
FDA starts review of new lung cancer drug, decision due Feb. 2027 - Stock Titan
Cullinan Therapeutics (CGEM) outlines 2026 virtual annual meeting - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Trading 6.2% HigherStill a Buy? - MarketBeat
We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash Wisely - Sahm
Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus
Is Cullinan (CGEM) stock showing weakness (+2.17%) 2026-04-18Professional Trade Ideas - Xã Châu Thành
Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: Analyzing the 112.72% Potential Upside - DirectorsTalk Interviews
Patterns Watch: Can Bausch Health Companies Inc expand into new markets - baoquankhu1.vn
Macro Review: Can Cullinan Therapeutics Inc benefit from deglobalization2026 Biggest Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Is Cullinan (CGEM) Stock priced for growth | Price at $14.49, Down 0.31%Safe Entry Stocks - Xã Vĩnh Công
Signal Recap: Whats the RSI of Cullinan Therapeutics Inc stock2026 Highlights & Real-Time Sentiment Analysis - baoquankhu1.vn
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Cullinan (CGEM) Stock better than industry peers | Price at $14.47, Down 2.62%Breakout Signals - Xã Vĩnh Công
JonesTrading Sticks to Their Buy Rating for Cullinan Management (CGEM) - The Globe and Mail
Weekly Earnings: What is Cullinan Therapeutics Incs valuation compared to sectorWeekly Trading Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
JonesTrading Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Bull Run: Whats the profit margin of Cullinan Therapeutics Inc2026 Fundamental Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 6.3%What's Next? - MarketBeat
Will Cullinan (CGEM) Stock Grow in 2026 | Price at $15.45, Up 7.07%Price Momentum - Xã Thanh Hà
Can Cullinan Therapeutics Inc outperform under higher oil prices2026 Setups & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
CGEM SEC FilingsCullinan Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison - defenseworld.net
Vanguard disaggregates holdings; reports 0 shares of Cullinan Therapeutics (CGEM) - Stock Titan
Volume Summary: Will Cullinan Therapeutics Inc benefit from AI trends2026 Fed Impact & Capital Protection Trade Alerts - baoquankhu1.vn
Cullinan Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):